<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03782623</url>
  </required_header>
  <id_info>
    <org_study_id>1595/2018</org_study_id>
    <nct_id>NCT03782623</nct_id>
  </id_info>
  <brief_title>Effect of Packed Red Blood Cell Transfusion on Eicosanoid Profiles in Plasma of Intensive Care Patients</brief_title>
  <acronym>EICOTRANS-p</acronym>
  <official_title>Effect of Packed Red Blood Cell Transfusion on Eicosanoid Profiles in Plasma of Intensive Care Patients - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this pilot study is to assess the time course of eicosanoid profiles in
      intensive care unit (ICU) patients requiring packed red blood cell (PRBC) transfusion.
      Moreover we will analyze the change of levels of eicosanoids in patient plasma prior and
      after a PRBC transfusion as well as its correlation with levels of eicosanoids in the
      transfused PRBCs. These data will then be used to determine the estimated effect size
      necessary for the planning of future larger studies. We hypothesize that transfusion of PRBCs
      will modulate the eicosanoid profile in ICU patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of plasma eicosanoid concentrations in ICU patients subjected to PRBC Transfusion at any time Point compared to baseline</measure>
    <time_frame>60 minutes prior to 90 minutes after packed red blood cell transfusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of plasma eicosanoid profiles after PRBC transfusion compared to prior to PRBC transfusion in ICU patients</measure>
    <time_frame>60 minutes prior to 90 minutes after packed red blood cell transfusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of plasma eicosanoid profiles in the transfused PRBCs and the change of their plasma levels in ICU patients</measure>
    <time_frame>60 minutes prior to 90 minutes after packed red blood cell transfusion</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Anemia</condition>
  <condition>Critical Illness</condition>
  <condition>Lung Transplantation</condition>
  <condition>Open Aortic Surgery</condition>
  <arm_group>
    <arm_group_label>Intensive care patients after elective open aortic surgery</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive care patients after bilateral lung transplantation</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Anesthetic intensive care patients, unplanned admission</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Analysis of eicosanoid profile prior to and after PRBC transfusion</intervention_name>
    <description>Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.</description>
    <arm_group_label>Anesthetic intensive care patients, unplanned admission</arm_group_label>
    <arm_group_label>Intensive care patients after bilateral lung transplantation</arm_group_label>
    <arm_group_label>Intensive care patients after elective open aortic surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Group 1: routine postoperative ICU patients after open aortic surgery Group 2: routine
        postoperative ICU patients with immunosuppression after lung transplantation Group 3: mixed
        postoperative ICU patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Exclusion Criteria:

          -  Age &lt;18 years or &gt;99 years

          -  Pregnancy

          -  &lt;12h since last PRBC transfusion

          -  intake/administration of acetylsalicylic acid in groups 2 and 3

          -  intake/administration of cysteinyl leukotriene receptor antagonists (e.g. montelukast)

          -  intake/administration of celecoxib, etoricoxib, parecoxib, ibuprofen, diclofenac, and
             naproxen in all groups

          -  glucocorticoids given within 24h of transfusion in groups 1 and 3

          -  treatment with calcineurin inhibitors (e.g. tacrolimus) in groups 1 and 3

          -  treatment with alemtuzumab in groups 1 and 3

          -  administration of protamine for heparin reversal in groups 2 and 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 16, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>David M Baron, MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

